New research from Karolinska Institutet in Sweden shows that the final stage of the normal inflammatory process may be disrupted in patients with Alzheimer's disease. A study published in the journal Alzheimer's & Dementia shows that levels in the brain and cerebrospinal fluid of the molecules necessary for tissue recovery through the clearance of harmful inflammatory substances are lower than normal in patients with Alzheimer's disease. The study also showed association between the lower levels of these molecules with impaired memory function.
Alzheimer's disease is the most common form of dementia, eventually leading to neuronal death associated with an increasing degree of memory impairment. As with other neurodegenerative diseases, Alzheimer's is characterised by an inflammatory process in the brain. Prolonged inflammation with the release of inflammatory and toxic substances can cause further damage and neuronal death.
The inflammatory process normally ends in what is known as resolution. This is an active process regulated by certain molecules, so called specialized pro-resolving mediators, where the tissue is cleared from microorganisms, debris from dead cells via an uptake mechanism (phagocytosis), and where the release of growth factors stimulates tissue repair.
Together with colleagues in the United States, researchers at Karolinska Institutet have now shown that the levels of resolution-regulating molecules in the brain and in the cerebrospinal fluid are lower in Alzheimer's disease than normal. The researchers have also shown that the lower levels of these molecules correlate with a lower degree of cognitive function, that is, memory capacity. The results are based on analyses of cerebrospinal fluid from 15 patients with Alzheimer's disease, 20 patients with mild cognitive impairment and 21 control subjects. The researchers also analysed brain tissue from 10 Alzheimer's patients and 10 control subjects.<
|Contact: Press Office|